Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers

BACKGROUND: Pegylated arginine deiminase (ADI-PEG 20) is a metabolism-based strategy that depletes arginine, resulting in tumoral stress and cytotoxicity. Preclinically, ADI-PEG 20 modulates T-cell activity and enhances the therapeutic efficacy of programmed death-1 (PD-1) inhibition. METHODS: A pha...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncoimmunology
Päätekijät: Chang, Kwang-Yu, Chiang, Nai-Jung, Wu, Shang-Yin, Yen, Chia-Jui, Chen, Shang-Hung, Yeh, Yu-Min, Li, Chien-Feng, Feng, Xiaoxing, Wu, Katherine, Johnston, Amanda, Bomalaski, John S., Wu, Bor-Wen, Gao, Jianjun, Subudhi, Sumit K., Kaseb, Ahmed O., Blando, Jorge M., Yadav, Shalini S., Szlosarek, Peter W., Chen, Li-Tzong
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Taylor & Francis 2021
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8276661/
https://ncbi.nlm.nih.gov/pubmed/34290906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2021.1943253
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia